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Abstract
Prevention of tissue damages at the site of Leishmania major inoculation can be achieved if the BALB/c mice are systemically
given L. major antigen (LmAg)-loaded bone marrow-derived dendritic cells (DC) that had been exposed to CpG-containing
oligodeoxynucleotides (CpG ODN). As previous studies allowed establishing that interleukin-4 (IL-4) is involved in the
redirection of the immune response towards a type 1 profile, we were interested in further exploring the role of IL-4. Thus,
wild-type (wt) BALB/c mice or DC-specific IL-4 receptor alpha (IL-4Ra)-deficient (CD11ccreIL-4Ra2/lox) BALB/c mice were
given either wt or IL-4Ra-deficient LmAg-loaded bone marrow-derived DC exposed or not to CpG ODN prior to inoculation
of 26105 stationary-phase L. major promastigotes into the BALB/c footpad. The results provide evidence that IL4/IL-4Ra-
mediated signaling in the vaccinating DC is required to prevent tissue damage at the site of L. major inoculation, as properly
conditioned wt DC but not IL-4Ra-deficient DC were able to confer resistance. Furthermore, uncontrolled L. major
population size expansion was observed in the footpad and the footpad draining lymph nodes of CD11ccreIL-4Ra2/lox mice
immunized with CpG ODN-exposed LmAg-loaded IL-4Ra-deficient DC, indicating the influence of IL-4Ra-mediated signaling
in host DC to control parasite replication. In addition, no footpad damage occurred in BALB/c mice that were systemically
immunized with LmAg-loaded wt DC doubly exposed to CpG ODN and recombinant IL-4. We discuss these findings and
suggest that the IL4/IL4Ra signaling pathway could be a key pathway to trigger when designing vaccines aimed to prevent
damaging processes in tissues hosting intracellular microorganisms.
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Introduction
Leishmania spp. infection in experimental mouse models provided
insights into the polarization of immune responses against
intracellular parasites, resulting either in self-healing local inflam-
mation (e.g., C57BL/6) or severe and fatal leishmaniasis (e.g.,
BALB/c) [1,2]. BALB/c mice fail to develop a protective
interferon (IFN)-c-mediated T helper (Th) 1 response to Leishmania
infection [3,4], but show a disease-promoting IL-4-driven Th2
response [5,6].
Dendritic cells (DC) are migratory antigen-presenting cells
(APC) which are highly specialized in uptake, processing and
presentation of pathogen-derived antigens via major histocompat-
ibility complex (MHC) molecules to T cells [7], resulting in the
cytokine-regulated differentiation into Th1 or Th2 cells. Activated
DC are characterized by high levels of MHC class II, CD80 and
CD86 molecules [8,9]. The ability of DC to release IL-12 in
response to microbial stimuli is considered to be pivotal for the
induction of Th1 responses [10,11].
We previously demonstrated that the Toll-like receptor (TLR) 9
ligand CpG oligodeoxynucleotides (ODN) is a potent inducer of
DC-derived IL-12, thus enabling DC to mediate complete and
long-lasting immunity to experimental leishmaniasis. Prophylactic
immunization with CpG ODN-activated and Leishmania major
antigen (LmAg)-loaded BMDC one week or even 16 weeks prior
to challenge has been shown to confer protection against L. major
and, furthermore, these cured mice resist a secondary challenge 10
weeks after primary infection showing no sign of disease up to 20
weeks after rechallenge [12]. Interestingly, protection was not
dependent on IL-12 secretion by the immunizing DC, as BALB/c
mice treated with LmAg-loaded IL-12p352/2 or IL-12p402/2
DC were resistant against L. major infection, but the availability of
recipient IL-12 was essential for the initiation of a protective
immune response by DC, as neutralization of IL-12 during T cell
priming diminished the protective effect of the vaccine [12].
The elaboration of DC-mediated vaccination strategies in animal
models can be used as a tool to enhance the knowledge of the
complex parasite-host interactions resulting in immunity against
intracellular pathogens. It is well established that the main inducer
of a Th2 response in Leishmania-susceptible BALB/c mice is IL-4
[13]. On the other hand, it has been shown that IL-4 has the ability
to instruct a Th1 response and resistance against L. major in BALB/c
mice. The presence of IL-4 during the initial phase of DC activation
results in an increased IL-12-driven Th1 response [14].
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To investigate the functional role of IL-4-mediated signaling
during Leishmania infection, various knock-out mice have been
generated. IL-4-deficient (IL-42/2) [15], as well as IL-4 receptor
alpha (IL-4Ra)-deficient BALB/c mice [16] are resistant to
infection with L. major. Cell-specific IL-4Ra-deficient (IL-4Ra2/2)
mice have been generated to investigate the impact of IL-4Ra-
mediated signaling on various cell types during Leishmania infection.
CD4+ T cell-specific LckcreIL-4Ra2/lox BALB/c mice show a resistant
phenotype [17], whereas DC-specific CD11ccreIL-4Ra2/lox BALB/c
mice are hyper-susceptible (Hurdayal et al., manuscript in prepara-
tion). Hyper-susceptibility in CD11ccreIL-4Ra2/lox mice is character-
ized by increased footpad swelling, the development of severe necrotic
lesions and high parasite dissemination into organs, demonstrating that
IL-4Ra signaling in DC is a necessity to control severe Leishmania
infection.
In the present study, IL-4Ra2/2 bone marrow-derived DC
(BMDC) from IL-4Ra2/2 BALB/c mice were used to investigate
the effect of IL-4Ra-mediated signaling in DC used as vaccine
carrier in L. major-susceptible mice. The results demonstrate that
IL-4Ra signaling in BMDC plays an important role in the vaccine-




All mice were kept under specific pathogen-free conditions.
Mice experiments were performed in strict accordance with the
German Animal Welfare Act 2006 (TierSchG) and the animal
protocol was approved by the government of Lower Franconia
(permission no. 55.2-2531.01-16/09) and by the Animal Research
Ethics Committee of the University of Cape Town (license
no. 009/042).
Mice and parasites
Sex- and age-matched wild-type (wt) BALB/c (Charles River
Breeding Laboratories, Sulzfeld, Germany) and CD11ccreIL-
4Ra2/lox BALB/c mice (Hurdayal et al., manuscript in prepara-
tion) were 6–8 weeks old at the onset of the experiments. IL-
4Ra2/2 BALB/c [18] mice were kindly provided by Gottfried
Alber (University of Leipzig, Germany).
The virulent L. major isolate (MHOM/IL/81/FE/BNI) was
maintained by continuous passage in BALB/c mice. Amastigotes
were isolated from lesions as previously described [19]. Promas-
tigotes were grown in vitro in blood-agar cultures. For the
preparation of LmAg, stationary-phase promastigotes were sub-
jected to three cycles of rapid freezing and thawing and diluted to
a final concentration of 16109 ml21 in phosphate-buffered saline
(PBS).
Preparation of bone marrow-derived dendritic cells
(BMDC)
DC were generated from bone marrow progenitors as described
previously [20]. Briefly, isolated bone marrow cells from 6–8 week-
old female BALB/c or IL-4Ra2/2 mice were cultured in RPMI
1640 medium (Invitrogen, Karlsruhe, Germany) in the presence of
200 U ml21 recombinant mouse granulocyte-macrophage colony-
stimulating factor (GM-CSF; PeproTech, London, United King-
dom). Fresh medium supplemented with GM-CSF was added to
the culture on days 3 and 6. After 10 days, non-adherent cells were
harvested and used for further experiments. These cells were
shown to have the typical myeloid DC morphology [12]. BMDC
were incubated for 4 hours in the presence of either 25 mg ml21
CpG ODN 1668 (59-TCCATGACGTTCCTGATGCT-39, Qia-
gen Operon, Cologne, Germany) or 20 ng ml21 recombinant
mouse IL-4 (rIL-4; BD Biosciences, Heidelberg, Germany), or a
combination of both, prior to the addition of LmAg for 18 hours.
Thereafter, the BMDC were washed and resuspended at
56106 ml21 in PBS.
Treatment of mice
BALB/c and CD11ccreIL-4Ra2/lox mice were treated with
56105 BMDC intravenously (i.v.) into the tail vein. Control mice
were treated with PBS. One week post vaccination the mice were
infected subcutaneously into the right hind footpad with 26105
stationary-phase L. major promastigotes in a final volume of 30 ml
in PBS. The course of infection was monitored weekly by
measuring the increase in footpad size of the infected versus the
noninfected footpad.
One. 3 or 6 weeks post infection, mice were sacrificed and single
cell suspensions from the infected footpads as well as the draining
popliteal lymph nodes were obtained. The parasite burden was
determined by limiting dilution assays as described previously [21].
Flow cytometry
Extracellular FACS. Lymphocytes were fixed with parafor-
maldehyde (PFA, 4%) and resuspended in FACS buffer containing
anti-Fc receptor antibodies (Ab) (purified rat anti-mouse CD16/
CD32) together with the appropriate combinations of the
following Ab: Biotin-streptavidin-horseradish peroxidase (SAV-
HRP)-conjugated anti-CD11c (HL3); fluorescein isothiocyanate
(FITC)-conjugated anti-I-Ad (AMS-32.1); and phycoerythrin (PE)-
conjugated anti-CD80 (16-10A1) (all Ab were purchased from BD
Biosciences, Heidelberg, Germany). Data was obtained using the
FACSCalibur flow cytometer (BD Biosciences, Heidelberg,
Germany) and analyzed using FlowJo (Tree Star Inc., CA, USA).
Intracellular FACS. 16106 lymphocytes were activated for
2 hours with 25 ng ml21 phorbol myristate acetate (PMA) and
1 mg ml21 ionomycin (both from Sigma-Aldrich, Deisenhofen,
Germany). Cultures were supplemented with 1 mM monensin for
the final 4 hours of culture. Cells were stained with biotin-SAV-
Author Summary
Cutaneous leishmaniasis is endemic in tropical and
subtropical regions of the world. Effective vaccination
strategies are urgently needed because of the emergence
of drug-resistant parasites and severe side effects of
chemotherapy. We previously established a DC-based
vaccination strategy to induce complete and long-lasting
immunity to experimental leishmaniasis using Leishmania
major antigen-loaded and CpG oligodeoxynucleotide-
activated DC as a vaccine carrier. In the present study we
investigated the role of IL-4Ra-mediated instruction of the
vaccinating DC and the host DC during induction of
protection against leishmaniasis. The results demonstrate
that IL-4Ra signaling in DC used as vaccine carrier plays an
important role in induction of protective immunity against
L. major infection, as only mice vaccinated with IL-4
responder DC are able to trigger effective Th1-mediated
immunity. The immunity is hallmarked by high levels of L.
major-induced bioactive IL-12 production in the lymph
nodes of vaccinated mice. Together, these findings
suggest that IL-4 is a strong adjuvant to induce Th1-
biased immunity against leishmaniasis and possibly other
infections with intracellular pathogens, indicating that IL-4
needs to be considered in the development of efficient
cell-mediated vaccination strategies.
IL-4R Signaling in DC Vaccination against L. major
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HRP-conjugated anti-CD11c (HL3) or FITC-conjugated anti-
CD4 Ab and fixed in 4% PFA, permeabilized with 0.2% saponin
and stained using PE-conjugated anti-IL-12 (C15.6), anti-IFN-c
XMG1.2) or anti-IL-4 Ab. IgG1 was used as isotope control (all
Ab from BD Biosciences, Heidelberg, Germany).
LmAg-stimulated cytokine release
56106 lymphocytes were cultured in the presence of LmAg
(parasite-to-cell ratio 30:1) or left untreated for 72 hours. The
levels of IL-4, IL-12p70 and IFN-c in the culture supernatants
were determined by sandwich ELISA using Ab pairs purchased
from BD Biosciences according to the manufacturer’s instructions.
Statistical analysis
Values are given as mean 6 SD and significant differences were
determined using Student’s t test (GraphPad Prism version 5, San
Diego, CA, USA).
Results
IL-4Ra signaling in BMDC used as vaccine carrier plays an
important role in the induction of resistance against L.
major infection
It has been shown that the Th2 key cytokine IL-4 can induce
protective Th1-mediated immunity in L. major-susceptible BALB/c
mice, as characterized by the secretion of high levels of DC-
derived IL-12 [14]. In order to investigate whether IL-4Ra
signaling in DC used as vaccine carrier is required to induce
protection against leishmaniasis, BMDC were generated from IL-
4Ra-deficient BALB/c mice or wt BALB/c mice. The BMDC
were activated with the TLR 9 ligand CpG ODN and pulsed with
LmAg prior to i.v. injection into naive BALB/c mice. Immunized
BALB/c or control mice were challenged with L. major one week
after vaccination, and the course of disease was monitored weekly.
In accordance with our previous study [12], mice immunized with
CpG ODN-activated and LmAg-pulsed wt BMDC were able to
control leishmaniasis. However, a significant progression of L. major
infection was observed in mice immunized with CpG ODN-activated
and LmAg-pulsed BMDC generated from IL-4Ra-deficient donors
(Figure 1A). Even though these mice were able to restrict footpad
swelling during the first three weeks, an uncontrolled lesion
development was observed in the advanced phase of infection.
Unprotected control mice showed a progressive course of disease with
massive footpad swelling and development of necrotic lesions, which
was not observed in mice immunized with conditioned IL-4Ra-
deficient BMDC. The lack of necrotic lesions in these mice can most
likely be explained by the delayed course of disease.
To determine whether the clinical outcome corresponds with
the control of parasite replication, we analyzed the parasite burden
in the infected footpads and the draining popliteal lymph nodes.
The results revealed a significant correlation between parasite
numbers and clinical outcome. The parasite burden at the site of
infection was reduced about 105-fold and within the draining
lymph node about 102-fold in protected mice (wt DC/CpG/
LmAg) compared to unprotected mice. BALB/c mice immunized
with IL-4Ra-deficient BMDC developed severe and progressive
leishmaniasis, even though the footpad swelling did not reach the
levels of PBS-treated mice. The parasite burden at the lesion site
was not affected, but a 10-fold reduction of parasite burden was
observed in the infected PLN. Equivalent results were obtained 3
weeks post infection (data not shown). Together, these findings
demonstrate that IL-4Ra-deficient BMDC were unable to induce
parasite clearance in the host organism.
The above results showed the importance of IL-4Ra-mediated
instruction of DC used as vaccine carrier. To investigate whether
DC of the host also require IL-4Ra signaling during vaccination, we
immunized and infected DC-specific IL-4Ra2/2 BALB/c mice
(CD11ccreIL-4Ra2/lox) (Figure 1B). Wt DC loaded only with LmAg
or CpG had no protective effect (data not shown), as expected. The
treatment of mice with conditioned wt BMDC induced protection
independent of whether DC of the host organism are IL-4
responders (Figure 1A) or not (Figure 1B). In contrast, immuniza-
tion with conditioned IL-4Ra2/2 BMDC was not capable to
induce the control of infection, as indicated by uncontrolled lesion
development and parasite burden at the site of infection. We
observed controlled footpad swelling in mice treated with PBS or
BMDC until 3 weeks post infection (Figure 1B). Delayed lesion
development was accompanied by reduced parasite burden and
high IFN-c response by LmAg-stimulated draining LN cells 3 weeks
post infection, but a Th1-biased immunity was not established
during the onset of infection (data not shown). In a complete IL-
4Ra-deficient system (neither vaccine carrier nor recipient DC are
IL-4 responders), an uncontrolled parasite replication in the infected
lymph nodes (102-fold increase compared to PBS group) was
observed. This observation is in contrast to the 10-fold reduction of
parasite burden within wt BALB/c mice immunized with IL-4Ra-
deficient BMDC (Figure 1A), indicating that the inhibition of IL-
4Ra signaling on host DC is detrimental and leads to increased
dissemination of parasites into lymph nodes. These results indicate
the importance of IL-4Ra-mediated instruction of DC used as
vaccine carrier to mediate protection against leishmaniasis.
Activation of LmAg-pulsed BMDC with rIL-4 alone does
not confer the potential to induce protective immunity
To confirm the hypothesis that IL-4Ra signaling is critical for the
ability of DC to induce resistance against leishmaniasis and to
address the possible combinations of how to activate BMDC used in
our vaccination strategy, we used BMDC generated from wt
BALB/c mice and stimulated these BMDC with either rIL-4 or
CpG ODN alone or a combination of both prior to loading with
LmAg. These differently treated BMDC were injected into wt
(Figure 2A) or CD11ccreIL-4Ra2/lox mice (Figure 2B) one week
prior to infection with L. major. The course of lesion development
was monitored weekly and the parasite burden at the site of
infection and the draining lymph node was analyzed. The results
show that in the absence of CpG ODN stimulation, rIL-4-treated
and LmAg-pulsed BMDC did not have the potential to induce
protective immunity with regard to the footpad swelling and the
parasite burden in the infected lymph nodes (102-fold increase
compared to positive control) and footpad (104-fold increase
compared to positive control) in wt (Fig. 2A) or CD11ccreIL-
4Ra2/lox (Fig. 2B) mice. We did not observe differences in the
course of disease in mice immunized with CpG ODN-activated
BMDC generated in the presence or absence of rIL-4. Both groups
of mice were clinically protected as indicated by controlled footpad
swelling and parasite burden in the examined tissues. The results
show that additional stimulation of IL-4-responsive BMDC with
rIL-4 during vaccine generation seems not to be essential to mediate
immunity to L. major, but that the boosting effect of additional rIL-4
(see below, Figure 5A) depends on properly activated BMDC.
IL-4Ra-deficient BMDC are less capable of inducing high
levels of activated and mature DC in the draining lymph
nodes of infected mice
Host-derived DC migrate to the site of infection, take up and
process antigens, which are then loaded onto MHC class I or II
IL-4R Signaling in DC Vaccination against L. major
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molecules. Thus activated, the DC differentiate into mature DC
and initiate the immune response while migrating to the local
draining lymph nodes, where they cross-talk with other cells of the
immune system [22,23]. For this reason, we analyzed the
activation and maturation status of CD11c+ cells in the lesion-
draining lymph nodes with regard to MHC class II and CD80
expression.
Wt or CD11ccreIL-4Ra2/lox mice that had been immunized
with properly conditioned IL-4Ra-deficient BMDC were less
capable of inducing high levels of activated and mature DC in the
draining lymph node (Figure 3). Clinically protected mice
(immunized with wt DC/CpG/LmAg, grey bars, and wt DC/
rIL-4/CpG/LmAg, lined bars) showed significantly higher per-
centages of CD11c+CD80+ and CD11c+MHCII+ cells compared
to mice that had been immunized with IL-4Ra2/2DC/CpG/
LmAg (black bars). These results were indicated in BALB/c mice
as early as one week post infection (data not shown).
These results demonstrate that upon immunization with IL-4-
responsive BMDC higher percentages of activated and mature
recipient DC are observed in lymph nodes of clinically protected mice.
Vaccination with IL-4Ra-deficient BMDC did not induce a
shift towards a protective Th1 response in BALB/c mice
We analyzed the secretion of IL-4, IL-12 and IFN-c by CD11c+
and CD4+ cells in the lymph nodes draining the lesions.
Intracellular FACS staining of PMA/ionomycin-stimulated lym-
phocytes revealed that clinically protected mice have higher levels
of Th1 cytokines and low levels of IL-4 in CD11c+ and CD4+ cells
(Figure 4A–D). Both types of vaccinating DC (conditioned wt
BMDC in the presence or absence of rIL-4) led to a higher IL-12
secretion by CD11c+ cells in the infected lymph nodes compared
to unprotected mice (Figure 4C). CD11c+ cells of protected mice
also displayed lower levels of IL-4 (Figure 4D). In comparison to
wt BALB/c mice, CD11c+ cells of CD11ccreIL-4Ra2/lox mice
showed per se lower levels of IL-12 and higher levels of IL-4.
CD4+ cells secreted lower amounts of IL-4 and higher amounts
of IFN-c in protected mice, compared to unprotected control mice
or mice immunized with conditioned IL-4Ra-deficient BMDC
(Figure 4A and B). Mice immunized with IL-4Ra-deficient BMDC
controlled to a certain level the IL-4 secretion by CD4+ cells
Figure 1. CpG ODN-activated and LmAg-loaded IL-4Ra2/2 BMDC fail to induce protection against leishmaniasis. BALB/c mice (A) or
CD11ccreIL-4Ra2/lox mice (B) were immunized i.v. with in vitro CpG ODN-activated and LmAg-loaded wt (%) or IL-4Ra2/2 (.) BMDC one week prior to
infection with L. major promastigotes. Control mice received PBS (#) before infection. The increase in size of the infected compared with the
noninfected footpad was measured weekly. The results are expressed as mean 6 SD of 10 animals. *, p,0.05, ***, p,0.0005 compared to PBS group
(#). The parasite burden of the infected footpad and the draining popliteal lymph nodes of BALB/c and CD11ccreIL-4Ra2/lox mice was determined six
weeks after infection. The results of two independent experiments (10 mice) are shown. *, p,0.05, ***, p,0.0005 compared to the respective PBS-
treated control group. PLN, popliteal lymph node. wt DC/CpG/LmAg, wild-type DC activated with CpG ODN and pulsed with L. major-antigen. IL-
4Ra2/2 DC, interleukin-4 receptor alpha-chain-deficient dendritic cells.
doi:10.1371/journal.pntd.0001721.g001
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(Figure 4B), but failed to control IL-4 secretion by CD11c+ cells
(Figure 4D) and failed to induce high levels of Th1 cytokines by
CD11c+ (Figure 4C) or CD4+ cells (Figure 4A). IL-4 secretion by
CD4+ cells of CD11ccreIL-4Ra2/lox mice is also increased
compared to wt BALB/c mice (Figure 4B).
These results demonstrate that IL-4Ra signaling in BMDC used
as vaccine carrier enables host DC to secrete high levels of
protective IL-12 and, thus, to control IL-4 secretion. This was
already indicated at 3 weeks post infection (data not shown).
IL-4Ra signaling in BMDC used as vaccine carrier is
important for the L. major-induced release of Th1
cytokines
Protection against leishmaniasis is associated with a Th1
immune response characterized by high levels of IL-12 and low
levels of IL-4. To analyze the potential of BMDC-based vaccines
to mediate a L. major-stimulated Th1 response, total lymphocytes
of all groups were collected six weeks post infection and stimulated
for 72 hours with LmAg. Subsequently, the cytokine levels of IL-4,
IL-12 and IFN-c were measured by ELISA.
LmAg stimulation of lymph node cells from protected BALB/c
mice caused the secretion of high levels of IL-12 and IFN-c and
low levels of IL-4, whereas mice immunized with IL-4Ra2/2 DC
showed a reversed cytokine pattern (Figure 5A). These results were
already indicated at one week post infection (data not shown).
Interestingly, the additional stimulation of properly activated IL-4-
responsive BMDC with rIL-4 resulted in elevated levels of IL-12
upon L. major infection in vivo in BALB/c mice.
Low levels of IL-4 were observed in CD11ccreIL-4Ra2/lox mice
independent of the presence or absence of IL-4Ra on DC used for
immunization, as in contrast to BALB/c mice, also conditioned
IL-4Ra2/2 BMDC were able to inhibit the release of IL-4 upon L.
major stimulation (Figure 5B). In line with the results obtained with
BALB/c mice, increased levels of IFN-c were observed in mice
immunized with properly conditioned wt BMDC, resulting in
protection against L. major. Immunization with conditioned IL-
4Ra2/2 BMDC was unable to induce the production of IL-12
and IFN-c, even though the L. major-stimulated IL-4 secretion was
controlled.
Elevated levels of IL-12 were only observed in wt BALB/c mice
upon immunization with properly activated and additionally rIL-
Figure 2. Stimulation of BMDC with rIL-4 prior to LmAg-loading is insufficient to induce protection against leishmaniasis. BALB/c (A)
or CD11ccreIL-4Ra2/lox mice (B) were immunized i.v. with rIL-4-stimulated and L. major antigen-loaded wt BMDC (wt DC/IL-4/LmAg) (n), a
combination of rIL-4 and CpG ODN-activated and L. major antigen-loaded wt BMDC (wt DC/IL-4/CpG/LmAg) (X) or CpG ODN-activated and L. major
antigen-loaded wt BMDC (wt DC/CpG/LmAg) (%) one week prior to infection with L. major. The footpad swelling was measured weekly. **, p,0.005,
***, p,0.0005 compared to positive control (wt DC/CpG/LmAg) (%). The parasite burden of the infected footpad and the draining popliteal lymph
nodes of BALB/c and CD11ccreIL-4Ra2/lox mice was determined six weeks after infection. The results of 10 mice (A) or 5 mice (B) are shown. *, p,0.05,
***, p,0.0005 compared to the respective positive control (wt DC/CpG/LmAg) (%).
doi:10.1371/journal.pntd.0001721.g002
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4-stimulated BMDC, hence indicating the role of IL-4-responding
host DC in the induction of IL-12 release upon L. major infection.
As already shown in Figure 4, wt BALB/c mice secrete higher
levels of Th1 cytokines, whereas CD11ccreIL-4Ra2/lox mice
secrete higher levels of IL-4. A complete IL-4Ra-deficient set-up
(vaccine and host) showed that IL-4Ra-mediated instruction of
DC is important to enhance protection against leishmaniasis, as
IL-4Ra-deficient DC were not capable of mediating resistance in
CD11ccreIL-4Ra2/lox mice.
Discussion
In the present study, we investigated the importance of IL-4Ra
triggering during DC-mediated vaccination against the protozoan
parasite L. major. The results show that complete protection against
otherwise lethal leishmaniasis required immunization of BALB/c
mice with IL-4-responsive BMDC, while IL-4Ra2/2 BMDC
failed to induce the restriction of lesion development. Even though
the footpad swelling was restricted during the first three weeks of
infection, a progressive course of disease with development of
severe and necrotic lesions was observed at later stages of infection.
In vitro studies showed that IL-4Ra-deficient BMDC secrete lower
amounts of IL-12 and higher amounts of IL-10 upon stimulation
with CpG ODN and LmAg compared to wt BMDC, which is
most probably the reason for the failure of immunization with IL-
4Ra-deficient BMDC, as no differences were observed regarding
the activation status of wt or IL-4Ra-deficient BMDC (data not
shown). Importantly, the levels of Leishmania-stimulated IL-12, the
most potent inducer of immunity to L. major [24,25], were
significantly increased in the lymph nodes of wt BALB/c mice
immunized with properly conditioned wt BMDC that had been
additionally activated with rIL-4. Elevated levels of IL-12 upon
stimulation with LmAg were only observed in IL-4 responder
recipients (wt BALB/c), but not in CD11ccreIL-4Ra2/lox mice,
demonstrating that IL-4 instruction of host DC is required to
induce elevated levels of IL-12 during L. major infection. BMDC
activated with rIL-4 alone were not able to mediate protection
against L. major, but induced elevated Leishmania-stimulated IL-4
levels in vivo (data not shown), skewing CD4+ T cells towards a Th2
cell phenotype and promoting susceptibility in BALB/c mice.
At the site of infection, neutrophils instruct DC recruitment and
activation, leading to Th1 cell activation and immunity to
microbial infection [26]. Our results extend these findings by
showing that upon immunization with IL-4-responsive DC, higher
percentages of activated and mature recipient DC are observed in
the lymph nodes draining the site of infection. In contrast, a less
pronounced increase of mature DC is found upon immunization
with IL-4 non-responder DC.
The Th1/Th2 paradigm of experimental leishmaniasis is
associated with IL-12- and IFN-c-mediated resistance or IL-4-
mediated susceptibility to L. major infection [2]. It is commonly
accepted that IL-4 is the hallmark cytokine mediating the
differentiation of naı̈ve Th0 cells into the Th2 phenotype.
However, the point that an IL-4-mediated Th2 response renders
mice necessarily susceptible has never been proven for visceral
leishmaniasis [27]. Furthermore, several data revealed a Th1-
Figure 3. Decreased levels of activated DC in the infected popliteal lymph nodes in mice vaccinated with IL-4Ra2/2 BMDC. The
lymphocytes of the draining popliteal lymph nodes of 5 BALB/c or 5 CD11ccreIL-4Ra2/lox mice, treated as indicated, were collected six weeks post
infection, surface-stained for CD11c, MHC class II and CD80 expression to determine the proportion of activated and mature DC in the lymph nodes
and analysed using FACSCalibur. The x-axis of the dot blots label CD11c and the y-axis MHC class II or CD80, as indicated. The numbers indicate % of
gated cells within the distinct quadrant. The mean 6 SD of 5 mice each is shown as bar graphs (white column: PBS-treated group, grey column: wt
DC/CpG/LmAg immunized group, black column: IL-4Ra2/2 DC/CpG/LmAg immunized group, lined column: wt DC/rIL-4/CpG/LmAg immunized
group). **, p,0.005 compared to the respective PBS- treated control group.
doi:10.1371/journal.pntd.0001721.g003
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promoting effect of IL-4 which is capable to prime for bioactive IL-
12. For example, treating human peripheral blood mononuclear cells
(PBMC) with IL-4 enhanced their IL-12 response to lipopolysaccha-
ride or Staphylococcus aureus [28], IL-12 production by human
monocytes during interaction with T cells was increased upon IL-4
stimulation [29] and IL-4 provided a negative feedback causing
murine as well as human DC to produce IL-12 [30]. IL-4 was
furthermore reported to be required for the induction of protective
Th1 cell responses to fungal infections, such as Candida albicans [31].
A protective role of IL-4 has also been shown for L. major
infection in susceptible BALB/c mice [14]. It is important to note
that the resistance-promoting role of IL-4 was only achieved when
IL-4 was strictly present during the initial activation of DC upon
infection. The presence of IL-4 during T cell priming resulted in
the development of Th2 cells, which even rendered resistant TCR
Vb4-deficient BALB/c mice susceptible to leishmaniasis. IL-4
acting on DC induced the generation of a protective Th1 immune
response against leishmaniasis in BALB/c mice [14].
Furthermore, it has been demonstrated that endogenous IL-4 is
necessary for effective drug therapy with sodium stibogluconate
against visceral leishmaniasis in BALB/c mice, as IL-4-deficient
mice responded poorly to this treatment and showed increased
parasite burdens in infected tissues [32]. Another example for IL-
4-promoted healing has been documented in BALB/c mice
vaccinated with a liposomal formulation against L. donovani, where
an initially vaccine-induced mixed Th1/Th2 response, character-
ized by high levels of IFN-c and IL-4, instructed an efficient Th1-
mediated resistance [33]. Our data are consistent with these
studies, showing that IL-4Ra signaling is important to enable DC
to induce a protective immune response in the recipient mice,
hallmarked by high levels of L. major-induced IL-12 production in
the lymph nodes of infected IL-4 responder mice.
Figure 4. IL-4Ra triggering of vaccine carrier leads to the control of IL-4 production by host lymphocytes. Lymphocytes of the draining
popliteal lymph nodes of 5 BALB/c or CD11ccreIL-4Ra2/lox mice, treated as indicated, were collected six weeks post infection and activated for 2 hours
with PMA-ionomycin before adding monensin for the final 4 hours of culture. The cells were stained for CD4 and IFN-c (A) or IL-4 (B) and for CD11c
and IL-12 (C) or IL-4 (D) and analysed using FACSCalibur. The x-axis of the dot blots label CD11c or CD4 and the y-axis IL-4, IL-12 or IFN-c as indicated.
The numbers indicate % of gated cells within the distinct quadrant. The bar graphs show the percentage of gated cytokine-secreting lymphocytes as
the mean 6 SD of 5 BALB/c (black column) or CD11ccreIL-4Ra2/lox mice (white column). *, p,0.05, **, p,0.005, compared to the respective PBS-
treated control group.
doi:10.1371/journal.pntd.0001721.g004
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Elevated IL-4 levels during the late phase of L. major infection in
resistant C57BL/6 mice were associated with the maintenance of
an existing protection [34], whereas susceptible BALB/c mice
showed elevated IL-4 levels only during the early phase of
infection [35]. These findings suggested a role of IL-4 in sustaining
protection during the chronic phase of leishmaniasis.
The results of the present study indicate a direct link between
IL-4Ra triggering of BMDC used for immunization and the
induction of elevated levels of IL-12 upon L. major infection in
BALB/c mice, which mediated complete protection against
otherwise lethal leishmaniasis. Resistance in leishmaniasis has
been reported to depend on DC-derived IL-12 [11], the inhibition
of Leishmania-specific IL-4-secretion by Vb4Va8 CD4+ T cells and
the induction of a Th1-dominated immune response in vivo [36].
Another aspect to give consideration to is that immunizing
CD11ccreIL-4Ra2/lox mice with IL-4Ra2/2 DC resulted in
progressive leishmaniasis, showing the importance of IL-4Ra
signaling not only in the immunizing DC but also in the host DC.
This complete IL-4Ra-deficient DC set-up caused uncontrolled
parasite dissemination into the draining lymph node, indicating
that the inhibition of IL-4Ra signaling in host DC is detrimental
and leads to increased dissemination of parasites into organs. In
general, CD11ccreIL-4Ra2/lox mice secrete elevated levels of IL-4
and decreased Th1 cytokines compared to wt BALB/c mice and
the effect of increased IL-12 secretion upon immunization with
additionally rIL-4-stimulated wt BMDC was not observed in these
mice, showing the important role of IL-4Ra signaling in host DC
for IL-12 production during L. major infection. Immunized
CD11ccreIL-4Ra2/lox mice showed controlled IL-4 levels inde-
pendent of the type of vaccine, while IL-4Ra-deficient BMDC
failed to induce a protective Th1 cytokine profile, resulting in a
nonprotective Th2 immune response. These results showed that
IL-4Ra signaling in the DC vaccine carrier is more critical than
the IL-4 responsiveness of host DC.
The present study enhances our understanding of the role of IL-
4Ra signaling in DC during cell-mediated vaccination against an
intracellular pathogen by showing that triggering this receptor is
essential to confer protection. Vaccination strategies against Th2-
Figure 5. IL-4Ra triggering of BMDC increases L. major-stimulated IL-12 secretion in vivo. BALB/c (A) or CD11ccreIL-4Ra2/lox mice (B) were
immunized with 56105 BMDC prepared as indicated and infected one week later with 26105 L. major promastigotes. Total lymphocytes of the
draining popliteal lymph nodes were collected six weeks post infection and incubated for 72 hours in the absence (white bars) or presence (black
bars) of LmAg. The levels of IL-4, IFN-c and IL-12 were measured by ELISA in the collected supernatants. The results of 5 mice are shown. *, p,0.05, **,
p,0.005 compared to the respective PBS-treated control group.
doi:10.1371/journal.pntd.0001721.g005
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related diseases, such as allergies or parasitic infections, should not
only concentrate on inhibiting anti-inflammatory Th2 responses
by inducing a strong Th1 phenotype, but need to consider the
proinflammatory effect of IL-4 as adjuvant on the vaccine
efficiency. An important aspect to be considered is that IL-4 as
well as IL-13 can signal through the common IL-4Ra chain. In
vitro results showed that wt BMDC stimulated with CpG ODN
and IL-4, but not IL-13, induced the secretion of elevated IL-12
levels compared to CpG ODN stimulated wt BMDC, and that
additional stimulation with IL-4 or IL-13 failed to induce elevated
levels of IL-12 secretion by IL-4Ra-deficient BMDC (data not
shown). These in vitro results strongly suggest that the elevated
secretion of DC-derived IL-12 is induced by IL-4 instruction of
DC and not by IL-13 instruction (see also Hurdayal et al.,
manuscript in preparation). The results of the present study
underline the importance of IL-4 signaling during vaccine design,
as IL-4Ra signaling in the DC vaccine carrier is more important
than IL-4Ra signaling in the host DC. Our results document the
crucial role of IL-4Ra signaling in DC-based vaccination against
leishmaniasis by promoting a protective Th1 immune response.
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